MedTrace Logo

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients

NCT00760175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2015-05-27

No results posted yet for this study

Summary

The influenza virus, commonly called the flu, is a common source of infection in lung transplant patients and can often lead to pneumonia and possibly rejection. The annual influenza vaccine is the most important strategy used to prevent infection but it is not effective in all lung transplant patients. It has been thought that the response to the vaccine may be improved if it is given into the skin (intradermal) rather than the muscle (intramuscular). We hypothesize that a significantly greater proportion of patients will respond to vaccination using the intradermal influenza vaccine compared to the intramuscular vaccine.

Conditions

  • Influenza Virus
  • Influenza Vaccine

Interventions

BIOLOGICAL

Vaxigrip (Aventis-Pasteur Canada)

The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.

Sponsors & Collaborators

  • University of Lausanne Hospitals

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Deepali Kumar, Msc, FRCPC · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • Canada
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760175 on ClinicalTrials.gov